Live Breaking News & Updates on Mirvetuximab Soravtansine

Stay updated with breaking news from Mirvetuximab soravtansine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 . ....

United States , North Carolina , Mirvetuximab Soravtansine , Conor Richardson , Clay Siegall , Kate Sasser , Taylor Schreiber , Exchange Commission , Ono Pharmaceutical Co Ltd , Development Rd Expenses , Shattuck Labs Inc , American Association For Cancer Research , Cancer Research , Annual Meeting , Chief Executive Officer , Ono Pharma , Milestones Expected , Platinum Resistant Ovarian Cancer , Cancer Cell , Ono Enter , Collaboration Agreement , Appoints Clay Siegall , Cash Equivalents , Clinical Trial , Shattuck Labs , Agonist Redirected Checkpoint ,

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial. ....

Los Angeles , United States , Gottfriede Konecny , Health Jonsson Comprehensive Cancer Center , University Of California , Department Of Gynecologic Medical Oncology , Gynecologic Medical Oncology , Jonsson Comprehensive Cancer , Mirvetuximab Soravtansine , Mirasol Trial ,

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer. ....

Rebeccal Porter , Harvard Medical School , Dana Farber Cancer Institute , Dana Farber , Mirvetuximab Soravtansine , Endometrial Cancer ,

Dr Konecny on the MIRASOL trial and Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

....

Los Angeles , United States , Gottfried Konecny , Department Of Medicine , University Of California , Gynecologic Oncology , Ovarian Cancer , Mirvetuximab Soravtansine ,

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers. ....

Emory University , United States , Susanc Modesitt , National Comprehensive Cancer Network , Winship Cancer Institute Of Emory University , Onclive State , Science Summit , Winship Cancer Institute , Gynecologic Oncology , Emory University School , Antibody Drug Conjugates , Onclive State Of The Science Summit , Trop2 And Her2 Targeted Adcs , Minimizing Toxicities , Mirvetuximab Soravtansine , Trastuzumab Deruxtecan , Sacituzumab Govitecan , Tisotumab Vedotin ,